8-K: Veradigm Board Member Resigns, Strategic Review Concludes Without Sale, Operational Review Initiated

Veradigm announces the resignation of a board member due to health reasons, the conclusion of its strategic alternatives review without a sale, and the commencement of an operational review to improve performance.

Summary

• Elizabeth A. Altman resigned from Veradigm's board of directors, including her role as Audit Committee Chair, effective January 28, 2025, due to health reasons.
• P. Gregory Garrison was appointed to the Audit Committee and as Interim Chair following Altman's resignation.
• The board size was reduced from six to five directors.
• Veradigm concluded its review of strategic alternatives, including a potential sale of the company, after engaging with over 30 parties but not receiving any final proposals.
• The company is engaging an independent strategic advisory firm to refine its go-forward plan and identify operational improvements.
• Veradigm intends to provide updated fiscal year 2023 and preliminary fiscal year 2024 estimated unaudited financial ranges and a business and audit update in mid-March 2025.
• The company plans to return to a regular cadence of providing investor updates, including financial guidance, following the March update.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the board member resignation, the unsuccessful strategic review, and the ongoing financial restatement. However, the company's commitment to transparency and operational improvements provides some positive signals.

Positives

• Veradigm is committed to transparency with investors, employees, customers, and partners.
• The company is focused on completing the restatement of its 2022 financial statements and becoming current in its financial reporting.
• Veradigm is engaging in an operational review to improve organizational alignment and generate profitable growth.
• The company plans to return to a regular cadence of providing investor updates, including financial guidance.

Negatives

• A board member resigned due to health reasons.
• The strategic review process did not result in a sale of the company.
• The company is still working on restating its 2022 financial statements and becoming current in its financial reporting.

Risks

• The company's ability to successfully execute its standalone strategy and deliver end-to-end solutions.
• The risk that the operational review may not identify sufficient improvements to drive profitable growth.
• The risk that the company may not be able to complete the restatement of its 2022 financial statements and become current in its financial reporting in a timely manner.
• The forward-looking statements are subject to significant risks and uncertainties as detailed in the company's filings with the SEC.

Future Outlook

Veradigm is focused on executing its standalone strategy, completing the restatement of its 2022 financial statements, and providing updated financial information in mid-March 2025, with plans to return to a regular cadence of investor updates and financial guidance.

Management Comments

• Greg Garrison, Chairman of the Board: 'On behalf of the entire Board, I thank Beth for the insight, dedication, and expertise that she brought to Veradigm. We are grateful for her valuable contributions and wish her all the best.'
• Greg Garrison, Chairman of the Board: 'The Board undertook the review of strategic alternatives with the primary objective of maximizing stockholder value. After engaging with over 30 parties, the Board has unanimously decided to end the strategic review. However, we remain open to all opportunities that enhance stockholder value.'
• Tom Langan, interim Chief Executive Officer of Veradigm: 'We believe Veradigm remains well-positioned to capitalize on the significant market opportunity ahead of us. Our leadership team has been working closely on developing the best path forward for our employees, our clients, and our stockholders.'

Industry Context

The healthcare technology sector is experiencing significant consolidation and strategic reviews as companies seek to maximize shareholder value. Veradigm's decision to conclude its strategic review without a sale reflects the challenges in finding suitable buyers and achieving desired valuations in the current market environment.

Comparison to Industry Standards

• Strategic reviews are common in the healthcare technology industry, with companies like Cerner (now Oracle Health) and athenahealth having undergone similar processes in recent years.
• The engagement of an independent strategic advisor is a standard practice to ensure objectivity and thoroughness in the review process.
• The number of parties engaged (over 30) is typical for a company of Veradigm's size and market position.
• The lack of final proposals suggests that potential buyers may have been concerned about the company's ongoing financial restatement or other factors.

Management Changes

Stakeholder Impact

• Shareholders may be disappointed by the unsuccessful strategic review and the lack of a sale.
• Employees may experience uncertainty during the operational review process.
• Customers may be concerned about the company's financial stability and its ability to provide ongoing services.
• The company's focus on completing the financial restatement and improving operational performance is intended to benefit all stakeholders in the long term.

Next Steps

• Veradigm will engage an independent strategic advisory firm to refine its go-forward plan.
• The company will provide updated fiscal year 2023 and preliminary fiscal year 2024 estimated unaudited financial ranges and a business and audit update in mid-March 2025.
• Veradigm plans to return to a regular cadence of providing investor updates, including financial guidance.

Key Dates